2017 - Transplantation Science Symposium

This page contains exclusive content for the member of the following sections: TTS, CTS, IPITA, ISODP, IXA, ITA, TID, IHCTAS, IPTA. Log in to view.

Tailored Immunosuppression and Chronic Rejection

8.40 - Repeated LPS Exposure Augments Alloimmune-Dependent and Airway-Targeted Chronic Lung Allograft Fibrosis in a Mouse Model

Presenter: Tatsuaki, Watanabe, Toronto, Canada


Tatsuaki Watanabe 0; Kristen Boonstra 0; Chihiro Konoeda 0; David Hwang 0; Zehong Guan 0; Mingyao Liu 0; Shaf Keshavjee 0; Tereza Martinu 0; StephenC Juvet 0

2Latner Thoracic Surgery Research Laboratories, University Health Network, Toronto, ON, Canada

Purpose: Outcomes after lung transplantation are poor in comparison with those of other solid organs mainly due to chronic lung allograft dysfunction (CLAD)[1], whose pathological correlates include airway and parenchymal fibrosis[2]. Because the lung allograft is constantly exposed to the external environment, CLAD is believed to result from a complex interplay of inflammatory, infectious and alloimmune factors[3]. Hence, experimental models based solely on alloimmunity may not simulate all relevant features of CLAD. We hypothesized that repeated administration of lipopolysaccharide (LPS) would augment alloimmunity and trigger chronic rejection and fibrosis in a mouse minor alloantigen-mismatched orthotopic lung transplant (OLT) model (C57BL/10 [B10, H-2b] → C57BL/6 [B6, H-2b]).

Methods: Three groups of mice underwent syngeneic OLT (SynOLT: B6 → B6) or allogeneic OLT (AlloOLT: B10 → B6). Each group was given or not given 6 or 8 doses of intratracheal LPS (5μg in 50μl PBS) on serial postoperative days (POD). Our 3 experimental groups are as follows: Group A underwent AlloOLT with LPS, Group B underwent AlloOLT without LPS, Group C underwent SynOLT with LPS. The grafts were histologically assessed 28 days after OLT in a blinded fashion. CT scans were performed on POD 7 and 27.

Results: LPS-treated mice showed bilateral lung infiltration on CT at POD 7. CT on POD 27 showed increased graft density in Group A. This change was not observed in Group B or Group C. Histological assessment of acute cellular rejection according to ISHLT criteria was as follows: Group A (score: 2.9), Group B (score: 1.7), Group C (score: 0.5) [Figure 1]. Parenchymal fibrosis was minimal in all groups. On the other hand, obliterative bronchiolitis, an important pathology seen in patients with CLAD, was found only in Group A (6 out of 10)[Figure 2 a-c. Masson trichrome stain. a: Group A, arrow indicates obliterated airway. b: Group B. c: Group C]. The right lungs of mice showed no rejection, inflammation, or airway obliteration on POD 28 [Figure 2d. HE stain of the right lung of Group A].{{AbstractFigure.1}}

Conclusion: Repeated intratracheal LPS exposure augments the alloimmune response and causes airway-dominant CLAD-like pathology in a minor alloantigen-mismatched mouse OLT model. These findings reveal an important pathway linking environmental exposure to lung allograft rejection that may allow discovery of new therapeutic targets in CLAD.

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.



Staff Directory


The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6